ArticleFrontiers in microbiology2012
Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing.
Article in Frontiers in microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Human germline-like monoclonal antibody against 5T4 enables potent ADC and CAR-T therapies for solid tumors.Acta pharmacologica Sinica · 2026Article
- Comprehensive characterization of V(D)J recombination from long-read transcriptomic data with VDJcraft.bioRxiv : the preprint server for biology · 2026Article
- Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries.Cell discovery · 2021Article
- Development of Coronavirus Treatments Using Neutralizing Antibodies.Microorganisms · 2021Review
- Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination.Vaccines · 2020Review
- Editorial: Next-Generation Sequencing of Human Antibody Repertoires for Exploring B-cell Landscape, Antibody Discovery and Vaccine Development.Frontiers in immunology · 2020Article
- Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient.The Journal of infectious diseases · 2018Article
- Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.Journal of virology · 2018Article
- 5' Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice.Frontiers in immunology · 2018Article
- A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin.Cell host & microbe · 2017Article
- Article
- Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2016Article
- Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody.Nature communications · 2015Article
- Article
- Identification of antigen-specific B cell receptor sequences using public repertoire analysis.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.Journal of virology · 2014Article
- Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.Journal of virology · 2014Article
- Antibody germline characterization of cross-neutralizing human IgGs against 4 serotypes of dengue virus.Biochemical and biophysical research communications · 2014Article
- Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.Current drug discovery technologies · 2014Review
- The promise and challenge of high-throughput sequencing of the antibody repertoire.Nature biotechnology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Our understanding of how antibodies are generated and function could help develop effective vaccines and antibody-based therapeutics against viruses such as HIV-1, SARS coronavirus (SARS CoV), and Hendra and Nipah viruses (henipaviruses). Although broadly neutralizing antibodies (bnAbs) against the HIV-1 were observed in patients, elicitation of such bnAbs remains a major challenge when compared to other viral targets. We previously hypothesized that HIV-1 could have evolved a strategy to evade the immune system due to absent or very weak binding of germline antibodies to the conserved epitopes that may not be sufficient to initiate and/or maintain an effective immune response. To further explore our hypothesis, we used the 454 sequence analysis of a large naïve library of human IgM antibodies which had been used for selecting antibodies against SARS CoV receptor-binding domain (RBD), and soluble G proteins (sG) of henipaviruses. We found that the human IgM repertoires from the 454 sequencing have diverse germline usages, recombination patterns, junction diversity, and a lower extent of somatic mutation. In this study, we identified antibody maturation intermediates that are related to bnAbs against the HIV-1 and other viruses as observed in normal individuals, and compared their genetic diversity and somatic mutation level along with available structural and functional data. Further computational analysis will provide framework for understanding the underlying genetic and molecular determinants related to maturation pathways of antiviral bnAbs that could be useful for applying novel approaches to the design of effective vaccine immunogens and antibody-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.